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ARTICLE
Human IgG1 antibodies suppress angiogenesis in
a target-independent manner
Sasha Bogdanovich1,21, Younghee Kim1,21, Takeshi Mizutani1,2,21, Reo Yasuma1,3,21, Laura Tudisco4,21, Valeria Cicatiello4,5,21,
Ana Bastos-Carvalho1, Nagaraj Kerur1, Yoshio Hirano1, Judit Z Baffi1, Valeria Tarallo1,4, Shengjian Li1, Tetsuhiro Yasuma1,
Parthasarathy Arpitha1, Benjamin J Fowler1, Charles B Wright1, Ivana Apicella4, Adelaide Greco6,7, Arturo Brunetti6,7, Menotti Ruvo8,
Annamaria Sandomenico8, Miho Nozaki2, Ryo Ijima3, Hiroki Kaneko3, Yuichiro Ogura2, Hiroko Terasaki3, Balamurali K Ambati9,10,
Jeanette HW Leusen11, Wallace Y Langdon12, Michael R Clark13, Kathryn L Armour13, Pierre Bruhns14,15, J Sjef Verbeek16,
Bradley D Gelfand1,17,18, Sandro De Falco4,19,21 and Jayakrishna Ambati1,20,21
Aberrant angiogenesis is implicated in diseases affecting nearly 10% of the world’s population. The most widely used anti-
angiogenic drug is bevacizumab, a humanized IgG1 monoclonal antibody that targets human VEGFA. Although bevacizumab does
not recognize mouse Vegfa, it inhibits angiogenesis in mice. Here we show bevacizumab suppressed angiogenesis in three mouse
models not via Vegfa blockade but rather Fc-mediated signaling through FcγRI (CD64) and c-Cbl, impairing macrophage migration.
Other approved humanized or human IgG1 antibodies without mouse targets (adalimumab, alemtuzumab, ofatumumab,
omalizumab, palivizumab and tocilizumab), mouse IgG2a, and overexpression of human IgG1-Fc or mouse IgG2a-Fc, also inhibited
angiogenesis in wild-type and FcγR humanized mice. This anti-angiogenic effect was abolished by Fcgr1 ablation or knockdown, Fc
cleavage, IgG-Fc inhibition, disruption of Fc-FcγR interaction, or elimination of FcRγ-initated signaling. Furthermore, bevacizumab’s
Fc region potentiated its anti-angiogenic activity in humanized VEGFA mice. Finally, mice deficient in FcγRI exhibited increased
developmental and pathological angiogenesis. These findings reveal an unexpected anti-angiogenic function for FcγRI and a
potentially concerning off-target effect of hIgG1 therapies.
Signal Transduction and Targeted Therapy (2016) 1, 15001; doi:10.1038/sigtrans.2015.1; published online 28 January 2016
INTRODUCTION
Dozens of monoclonal antibodies are approved by the United
States Food and Drug Administration, European Medicines
Agency, and other regulatory agencies for treating numerous
diseases including age-related macular degeneration (AMD),
asthma, autoimmune disorders and multiple cancers. These drugs
are used in millions of people worldwide with global sales
exceeding $50 billion.1 In addition, there are hundreds of ongoing
clinical trials evaluating various other monoclonal antibodies.1
Bevacizumab (Avastin), a humanized monoclonal IgG1 that
targets VEGFA,2 inhibits blood vessel growth and has been
approved for treating multiple cancers,3 and is widely used to
treat neovascular AMD.4 Bevacizumab is exquisitely specific for
human VEGFA, having no measurable binding affinity for, or ability
to functionally inhibit, murine Vegfa.5–7 Surprisingly, numerous
reports claim an anti-angiogenic effect of bevacizumab in various
murine models of neovascularization.8–14 Yet nearly all these
reports have compared bevacizumab with saline or no treatment
controls rather than to a biologically appropriate human IgG1
control. We suspected, therefore, that the angioinhibitory effect of
bevacizumab in murine models was misattributed to blockade of
Vegfa, and was instead due to an intrinsic property of the IgG1
molecule independent of its antigenic specificity, namely a target-
independent effect.
In this study, we found that bevacizumab, and numerous other
therapeutic human IgG1 antibodies, as well as mouse IgG2a,
suppressed angiogenesis in mice via FcγRI, the high-affinity IgG
receptor.15–17 These effects were observed both with local and
systemic administration of these antibody preparations at doses
similar to or identical to those used in humans for various
diseases.
A prospective randomized clinical trial reported in patients with
corneal angiogenesis that bevacizumab, a full-length antibody
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that neutralizes human VEGFA activity and is able to bind FcγRs, is
superior to ranibizumab, a humanized IgG1 Fab fragment that
blocks human VEGFA but cannot bind FcγRs, in inhibiting
angiogenesis.18 Our findings provide a molecular basis for this
clinical observation. In contrast, clinical trials in patients with
choroidal angiogenesis found no significant difference in the
effects of bevacizumab versus ranibizumab, each tested at a single
dose, on angiogenic lesion size.4,19 Our findings suggest that the
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dose of bevacizumab required to achieve FcγRI-mediated anti-
angiogenic activity is roughly eight times higher than the dose
used in these trials, which is sufficient only to neutralize human
VEGFA, thereby providing a molecular rationale for testing such
higher doses.
Angiogenic diseases collectively affect half-a-billion people;20
together, our data provide evidence that human IgG1 antibodies,
as a class, form an important group of angioinhibitors, potentially
fill the need for developing inexpensive generic human IgG1
drugs,21 and raise awareness for monitoring possible unintended
effects on blood vessels by these widely used therapeutics. We
also found increased pathological and developmental angiogenic
responses in mice lacking FcγRI, suggesting that endogenous Igs
also have a role in vascular patterning.
MATERIALS AND METHODS
Animals
All animal experiments were in accordance with the guidelines of the
relevant institutional authorities. Male mice, aged 4–8 weeks, were
randomized 1:1 to treatment with active drug versus inactive drug or
control treatments.
Corneal angiogenesis
Nylon sutures (Mani, Utsunomiya, Japan) were placed into the corneal
stroma of mice, and on day 10 after injury, we calculated the mean
percentage CD31+Lyve1− blood vessel areas for corneal flat mounts with
ImageJ (US National Institutes of Health, Bethesda, MD, USA) as previously
reported.22,23
Choroidal angiogenesis
Laser photocoagulation (OcuLight GL, IRIDEX, Mountain View, CA, USA)
was performed on both eyes of mice to induce neovascularization, and on
day 7 after injury, choroidal angiogenesis volumes were measured by
scanning laser confocal microscopy (TCS SP5, Leica, Wetzlar, Germany) as
previously reported with 0.7% FITC-conjugated Isolectin B4 (Vector
Laboratories, Burlingame, CA, USA).24,25 For intravitreous administration
in choroidal angiogenesis experiments, drugs was administered into
the vitreous humor of mice using a 33-gauge double-calibre needle
(Ito Corporation, Tokyo, Japan) as previously described.26
Hind limb ischemia angiogenesis
Unilateral proximal femoral artery ligation was performed as previously
described,27 and on day 7 after surgery, both anterior and posterior
muscles from ischemic and non-ischemic hind limbs were collected and
processed for immunohistochemical analysis for vessel quantification.
Color laser Doppler analysis was also performed using a dedicated Laser
Doppler Perfusion Imaging System (LDPI, PeriScan PIM II System,
Perimed AB, Järfälla, Sweden).
Statistical analyses
Choroidal angiogenesis volumes per laser lesion were compared by
hierarchical logistic regression using repeated measures analysis as
previously described.28 For other comparisons, we used the Mann–
Whitney U-test with Bonferroni correction for statistical comparison of
multiple variables. Results are expressed as mean± s.e.m. Type-I error not
exceeding 0.05 was deemed significant.
RESULTS
Bevacizumab and human IgG1 antibodies inhibit angiogenesis
in mice
Bevacizumab has no detectable binding to mouse Vegfa
by surface plasmon resonance and does not block mouse
Vegfa-induced retinal capillary endothelial cell proliferation.5–7
To further verify that bevacizumab does not functionally neutralize
mouse Vegfa, we tested its ability to inhibit the activation of the
Vegfr2 receptor tyrosine kinase in mouse Py4 hemangioma
endothelial cells. As expected, bevacizumab inhibited Vegfr2
phosphorylation induced by human VEGFA but not by mouse
Vegfa (Figure 1a).
We tested the effects of bevacizumab in a mouse model of
suture injury-induced corneal angiogenesis, which is pathophy-
siologically relevant to the human condition and is driven in large
part by Vegfa. We found that administration of bevacizumab into
the cornea by intrastromal injection (4 μl of the commercial
25 mg/ml preparation—a dose similar to that used in humans,
when corrected for relative size) inhibited corneal angiogenesis by
46% compared with phosphate-buffered saline (PBS) administra-
tion in wild-type mice (Figure 1b). This angioinhibition occurred in
a dose-dependent fashion (Supplementary Figure 1). We also
tested whether ranibizumab, a humanized monoclonal IgG1 Fab
Figure 1. Bevacizumab inhibited mouse angiogenesis via Fc region. (a) Western blot shows that bevacizumab inhibited Vegfr2
phosphorylation (pVegfr2) in Py4 mouse hemangioma endothelial cells when treated with human VEGFA, but not when treated with
mouse Vegfa, after 10 min. Image representative of three experiments. (b) Bevacizumab and human IgG1, but not ranibizumab, decreased
corneal angiogenesis in wild-type mice. Area of angiogenesis was measured 10 days after suture injury and normalized to PBS group. n= 10–38.
Representative photos of wild-type mouse eyes (upper row) and corneal flat mounts (lower row) showing reduced growth of blood vessels
(CD31+, red) in eyes treated with bevacizumab or human IgG1, but not in eyes treated with ranibizumab. Scale bars, 100 μm. (c) Bevacizumab
and human IgG1, but not ranibizumab, suppressed choroidal angiogenesis in wild-type mice 7 days after laser injury compared with PBS
(experiment performed in JA laboratory). Images depict representative choroidal angiogenesis lesions (endothelial cells stained in green) in
each treatment group. n= 12–20. (d, e) Treatment of ischemic hind limb with bevacizumab or human IgG1 in wild-type mice suppressed
muscle revascularization and decreased blood vessel perfusion, as seen in representative laser Doppler perfusion images (top), and
measured blood flow in the ischemic limbs (bottom), normalized to the contralateral non-ischemic limbs, 7 days after surgery. n= 6. I/NI,
ischemic/non-ischemic. Bevacizumab and human IgG1, but not ranibizumab, treatment of ischemic limbs reduced muscle angiogenesis
(CD31+, brown) as seen in representative images of muscle CD31 immunolocalization (e), and quantification of muscle CD31
immunolocalization (bottom), normalized to the contralateral non-ischemic limbs. (f) The Fc fragments, not the Fab fragment, of
bevacizumab suppressed corneal angiogenesis in wild-type mice. Area of angiogenesis was measured 10 days after suture injury and
normalized to PBS group. n= 10–38. (g) Co-administration of a peptide that prevents IgG-Fc binding to FcγR, but not a control peptide,
blocked inhibition of choroidal angiogenesis by bevacizumab in wild-type mice. (h) Co-administration of an IgG-Fc inhibitory peptide, but not
a control peptide, blocked inhibition of muscle angiogenesis (CD31+, brown) by bevacizumab, as seen in representative images of muscle
CD31 immunolocalization (left), and quantification of muscle CD31 immunolocalization (right), normalized to the contralateral non-ischemic
limbs. Scale bar, 100 μm. n= 6. (i) Bevacizumab suppressed choroidal angiogenesis in wild-type mice to the same extent as SU1498, a small
molecule tyrosine kinase inhibitor of Vegfr2. Combined administration of bevacizumab and SU1498 suppressed choroidal angiogenesis to a
greater extent than either of the agents alone. n= 6. (j) Choroidal angiogenesis, augmented by administration of human VEGFA, was
suppressed to similar extents by ranibizumab, bevacizumab-Fab, bevacizumab-Fc and human IgG1; and, to a greater extent, by bevacizumab.
n= 6–8. (k) Bevacizumab suppressed choroidal angiogenesis to a greater extent than ranibizumab in the humanized VEGFA mouse, a
transgenic model that expresses a VEGFA protein that can be neutralized by both bevacizumab and ranibizumab. n=6. Results are means± s.e.m.
*Po0.05 compared with PBS (b–h, k) or with vehicle (i) or with PBS+human VEGFA (j).
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fragment that binds human VEGFA but not mouse Vegfa6,29 and is
approved for the treatment of neovascular AMD, was anti-
angiogenic in this model. We confirmed that, like bevacizumab,
ranibizumab inhibited Vegfr2 phosphorylation induced by human
VEGFA but not by mouse Vegfa (Supplementary Figure 2).
However, unlike bevacizumab, ranibizumab, at equimolar
amounts, did not inhibit corneal angiogenesis (Figure 1b).
Interestingly, the control isotype human IgG1 for bevacizumab
also reduced corneal angiogenesis in wild-type mice in a dose-
dependent fashion (Figure 1b and Supplementary Figure 3).
We next tested a mouse model of laser injury-induced choroidal
angiogenesis, a widely used model of neovascular AMD that is
driven in large part by Vegfa and has been predictive of the
success of anti-VEGFA therapies in humans. Independent testing
by three different laboratories (JA, YO and HT) determined that
intraocular administration of bevacizumab (1 μl of the commercial
25 mg/ml preparation—a dose approximately eight times that
was used in humans, when corrected for relative size) by
intravitreous injection inhibited choroidal angiogenesis by
40–45% in wild-type mice compared with PBS administration,
whereas an equimolar amount of ranibizumab did not do so
(Figure 1c and Supplementary Figure 4). Similar to the corneal
model, the isotype human IgG1 and human IgG1-Fc also
suppressed choroidal angiogenesis in wild-type mice (Figure 1c
and Supplementary Figure 4).
We tested the effect of bevacizumab in a third model of
angiogenesis, induced by hind limb ischemia produced by femoral
artery ligation, which is a model of peripheral arterial disease.
Intramuscular injection of either bevacizumab or isotype control
human IgG1 suppressed limb revascularization and diminished
perfusion, as monitored by color laser Doppler imaging, compared
with PBS injection (Figure 1d). There was a corresponding
reduction in angiogenesis by 47–59% in the bevacizumab- or
human IgG1-treated limbs compared with the PBS-treated limbs,
whereas ranibizumab did not suppress angiogenesis (Figure 1e).
These data support the concept that human IgG1 antibodies can
suppress angiogenesis in multiple tissues.
Fc portion of human IgG1 critical for angioinhibition
Since bevacizumab and ranibizumab had nonsynonymous effects
on angiogenesis in these mouse models, we suspected that the
anti-angiogenic action of bevacizumab was due not to Vegfa
neutralization but rather to IgG1-Fc-mediated effects. We con-
firmed that angioinhibition was due to the Fc, and not Fab,
portion of bevacizumab by administering separately its Fab and Fc
fragments as prepared from papain enzymatic digestion of the
antibody (Supplementary Figure 5). Bevacizumab-Fab, but not
bevacizumab-Fc, inhibited VEGFA-induced Vegfr2 phosphoryla-
tion, consistent with the location of the VEGFA-binding residues
on the Fab fragment and indicating that the VEGFA neutralizing
properties of bevacizumab were not affected by enzymatic
digestion (Supplementary Figure 5). In contrast, bevacizumab-Fc,
but not bevacizumab-Fab, reduced corneal angiogenesis in
wild-type mice (Figure 1f), indicating that bevacizumab’s angioin-
hibitory activity in mice is due to its Fc domain and not because of
binding Vegfa.
Human IgG1 and human IgG1-Fc also suppressed choroidal
angiogenesis in wild-type mice (Figure 1c and Supplementary
Figure 4). A peptide that prevents the binding of IgG to FcγRs by
interacting with the Fc portion of IgG (IgG-Fc peptide inhibitor),30
but not a control peptide, eliminated the ability of bevacizumab to
inhibit choroidal and hind limb angiogenesis in wild-type mice
(Figure 1g and h), confirming a role for FcγR in these models.
We sought to determine whether human IgG1s would suppress
angiogenesis not only when exogenously administered but also if
produced endogenously. Therefore, we performed in vivo trans-
fection of a plasmid encoding human IgG1-Fc coupled to an
IL2-secretory sequence (phIgG1-Fc) by injecting it into the
subretinal space of wild-type mice before laser injury. We found
that phIgG1-Fc reduced choroidal angiogenesis in wild-type mice
compared with a control null plasmid (Supplementary Figure 6).
These data show that angiogenesis can be suppressed not only by
exogenous administration of human IgG1 antibodies but also by
endogenous overexpression of their Fc region.
Bevacizumab and human IgG1 antibodies inhibit angiogenesis in
humanized VEGF mice
Ranibizumab, which targets human VEGFA and does not have an
Fc region, is effective in treating neovascular AMD in humans.31,32
We sought to compare the relative anti-angiogenic efficacies of
bona fide VEGFA targeting and of FcγR-mediated signaling. First
we found that the extent of suppression of choroidal angiogenesis
by bevacizumab (48%) in wild-type mice was similar to that
achieved by SU1498 (49%), a small molecule tyrosine kinase
inhibitor of Vegfr2 (Figure 1i), and to that achieved by various
inhibitors of Vegfa reported in previous studies (~40–55%).28,33–36
We also found that bevacizumab potentiated the angioinhibitory
effects of SU1498 (Figure 1i).
Next we used a model in which laser injury-induced choroidal
angiogenesis is augmented by prior intravitreous administration
of human VEGFA.37 In this model where angiogenesis is driven
both by human VEGFA and endogenous mouse pathways, we
found that ranibizumab and bevacizumab-Fab, which target
human VEGFA but do not contain an Fc region, suppressed
angiogenesis to a similar extent as bevacizumab-Fc and human
IgG1, which contain an Fc region but do not target human VEGFA
(Figure 1j). In addition, full-length bevacizumab suppressed
angiogenesis to a greater extent than any of the pure anti-
VEGFA or Fc-containing agents alone, further indicating that
modulating these two anti-angiogenic pathways simultaneously
can be additive. Next, we studied ‘humanized VEGFA’ mice,6
wherein the mouse Vegfa gene was mutated such that its protein
product could be neutralized by bevacizumab and ranibizumab. In
this model, we found that bevacizumab suppressed choroidal
angiogenesis to a significantly greater extent than ranibizumab
(Figure 1k). Collectively these data demonstrate that the Fc region
of bevacizumab can potentiate its anti-angiogenic effect in
systems where human VEGFA is present.
FcγRI necessary for human IgG1-induced angioinhibition
We performed additional experiments to investigate the nature of
the Fc-mediated anti-angiogenic effect of bevacizumab. It is
known that deglycosylation of human IgG1 dramatically reduces
its binding to both human and mouse FcγRs.38–40 We found that
deglycosylated bevacizumab, despite retaining its ability to inhibit
human VEGFA-induced Vegfr2 phosphorylation (Supplementary
Figure 7), did not reduce choroidal angiogenesis in wild-type mice
(Figure 2a). These data suggest that the anti-angiogenic effect of
bevacizumab in mice is mediated by an endogenous FcγR that
binds human IgG1.40
We found that bevacizumab did not suppress choroidal
angiogenesis in Fcer1g− /− (a.k.a. FcRγ− /−) mice (Figure 2b), which
lack the common gamma chain of the activating FcγRs: FcγRI,
FcγRIII and FcγRIV. To determine which activating FcγR was
responsible, we tested mice lacking these receptors. First, we
tested the involvement of FcγRI (encoded by Fcgr1), and found
that bevacizumab failed to inhibit corneal or choroidal angiogen-
esis in Fcgr1− /− mice (Figure 2c). In contrast, bevacizumab
inhibited corneal and choroidal angiogenesis in mice lacking
Fcgr3 (Supplementary Figure 8), which encodes FcγRIII, and in
mice lacking Fcgr4 (Supplementary Figure 9), which encodes
FcγRIV. Supporting the latter result, bevacizumab did not inhibit
angiogenesis in Fcgr1−/−; Fcgr2b−/−; Fcgr3−/−; Fcer1a−/− and
Fcer2a−/− mice, which express FcγRIV but not any of the other
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IgG or IgE receptors41 (Supplementary Figure 10). Human IgG2
binds to mouse FcγRII and FcγRIII, but not to FcγRI.40 The human
IgG2 denosumab (Prolia: anti-RANKL) did not inhibit corneal or
choroidal angiogenesis in wild-type mice (Figure 2d), suggesting
that binding to FcγRI is required for IgG-induced angioinhibition.
We also found that subretinal transfection of a plasmid
encoding a mutant form of human IgG1-Fc engineered with
point mutations that eliminate binding to FcγRI or of a plasmid
encoding human IgG2-Fc did not suppress choroidal angiogenesis
in wild-type mice (Supplementary Figure 11), further supporting
Figure 2. Bevacizumab inhibited mouse angiogenesis via FcγRI. (a) Deglycosylated bevacizumab did not suppress choroidal angiogenesis in
wild-type mice; however, choroidal angiogenesis was inhibited by bevacizumab subjected to mock treatment. The deglycosylation buffer had
no effect on choroidal angiogenesis. n= 8–14. (b) Bevacizumab did not suppress corneal or choroidal angiogenesis in Fcer1g−/− mice. n= 8–10.
(c) Bevacizumab did not inhibit corneal or choroidal angiogenesis in Fcgr1−/− mice. No significant difference between groups. n= 10–13.
(d) Denosumab did not suppress corneal or choroidal angiogenesis in wild-type mice. n= 6–8. No significant difference between groups.
(e) Bevacizumab inhibited corneal angiogenesis in FcγR humanized mice. n= 8. Results are means± s.e.m. *Po0.05 compared with PBS.
(f) Bevacizumab, but not denosumab, inhibited choroidal angiogenesis in FcγR humanized mice. n= 6–8. (g) Co-administration of a 17+2-nt
cholesterol conjugated human FCGR1A siRNA, but not a 17+2-nt cholesterol-conjugated control Luc siRNA, blocked inhibition of choroidal
angiogenesis by bevacizumab in FcγR humanized mice. n= 8. (h) Co-administration of an IgG-Fc inhibitory peptide, but not a control peptide,
blocked inhibition of choroidal angiogenesis by bevacizumab in FcγR humanized mice. n= 8. Results are means± s.e.m. *Po0.05 compared
with PBS (a, e–h).
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the concept that angioinhibition is a target-independent class
effect of human or humanized IgG1 monoclonal antibodies that is
mediated via FcγRI.
Administration of bevacizumab by i.v. injection every other day
(to account for the 6.5-fold higher serum clearance rate in mice
compared with humans,42 in whom it is administered weekly or
every other week) also suppressed choroidal angiogenesis in
wild-type mice in a dose-dependent fashion, but did not do so in
Fcgr1− /− mice (Supplementary Figure 12). Collectively, these data
indicate that bevacizumab reduces mouse angiogenesis via FcγRI
and not via Vegfa inhibition.
Bevacizumab reduces angiogenesis in FcγR humanized mice
Although human IgG1 binds both mouse FcγRI and human Fcγ
RI,40 the structural diversity and unique cellular expression
patterns of mouse and human FcγRs are not synonymous.43 The
generation of an FcγR humanized mouse via transgenic expres-
sion of the entire human FcγR family, under the control of their
human regulatory elements, on a genetic background lacking all
mouse FcγRs has enabled better prediction of the functional
consequences of engaging human FcγRs by IgGs.44 In these FcγR
humanized mice, we found that intracorneal bevacizumab
reduced corneal angiogenesis just as in wild-type mice
(Figure 2e). Bevacizumab also reduced choroidal angiogenesis in
FcγR humanized mice whereas the human IgG2 denosumab did
not (Figure 2f). As human IgG2 can bind human FcγRII and human
FcγRIII but not human FcγRI,45 this result supports the notion that
interaction with human FcγRI is mandatory for the anti-angiogenic
effect of IgGs in our models. The angioinhibitory effect of
bevacizumab was blocked by both the IgG-Fc peptide inhibitor
and a cholesterol-conjugated28 FCGR1A siRNA (Figure 2g and h).
These data demonstrate that target-independent FcγRI-mediated
angioinhibitory activity of humanized monoclonal IgG1 antibodies
is operative in a FcγR humanized system.
Bevacizumab interacts with FcγRI and initiates signaling in vivo
As we found that bevacizumab suppressed angiogenesis via FcγRI,
we tested whether bevacizumab binds FcγRI in vivo using two
complementary strategies. First, using a pull-down assay, we
found that biotinylated bevacizumab, but not denosumab, that
was injected into wild-type mouse corneas following suture injury
co-precipitated with mouse FcγRI (Figure 3a). Next, we injected
unlabeled bevacizumab into the corneas of FcγR humanized mice
that were subjected to suture injury, and found that immuno-
precipitation of human FcγRI pulled down human IgG1
(Figure 3b). Collectively, these data demonstrate an in vivo
interaction between bevacizumab and both human and mouse
FcγRI. In addition, bevacizumab injected into the corneas
of FcγR humanized mice following suture injury-induced FcγRI
phosphorylation (Figure 3b).
Crosslinking of FcγRI by human IgG1 aggregates can activate
FcγRI. However, we found, using dynamic light scattering, no
evidence of aggregation of bevacizumab at the administered dose
(Supplementary Figure 13), as might be expected from a clinical
Figure 3. Bevacizumab interacted with, induced phosphorylation of, and upregulated abundance of FcγRI in vivo. (a) Wild-type mouse corneas
that had been administered biotinylated bevacizumab or biotinylated denosumab following suture injury were subjected to streptavidin pull-
down and immunoblotting for mouse FcγRI. Biotinylated bevacizumab, but not denosumab, interacted with mouse FcγRI in vivo. Anti-
streptavidin immunoblotting confirmed efficient pull-down of both biotinylated antibodies. (b) FcγR humanized mouse corneas that had
been administered bevacizumab or PBS following suture injury were subjected to immunoprecipitation of human FcγRI followed by
immunoblotting for human IgG1 or phosphotyrosine. Bevacizumab, but not PBS, interacted with and induced phosphorylation of human
FcγRI in vivo. Reprobing confirmed efficient immunoprecipitation of human FcγRI in both bevacizumab- and PBS-treated corneas. Each image
is representative of three experiments (a, b). (c) Bevacizumab, but not PBS, increased Fcgr1 mRNA abundance in RAW264.7 mouse
macrophages and in wild-type mouse corneas following suture injury, as monitored by real-time reverse transcription PCR, and FcγRI protein
abundance in RAW264.7 cells, as monitored by western blotting. Densitometry of FcγRI normalized to Vinculin shown. n= 4–6. Results are
means± s.e.m. *Po0.05 compared with PBS.
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grade preparation. This suggests that monomeric bevacizumab
can induce FcγRI-mediated signaling in vivo in the systems
we studied. Indeed, monomeric IgG engagement of other
activating FcγRs has been shown to induce phosphorylation and
signaling.46,47 Nevertheless, we cannot exclude the possibility that
once the non-aggregated liquid formulation is administered into
the mouse, bevacizumab might undergo in vivo aggregation.
However, this seems unlikely given the lack of any known mouse
ligand for bevacizumab. Moreover, if such in vivo aggregation of
bevacizumab occurred in the mouse, it would also be expected to
occur in human eyes because of the similar dose injected and the
presence of a bona fide ligand—human VEGFA.
We next wondered how bevacizumab could bind FcγRI given
the high serum concentration of endogenous mouse IgG that
might be expected to compete for binding. Indeed, it has been
shown that FcγR can still bind IgG under serum conditions48,49 and
can execute numerous biological functions in vivo in response to
exogenous mouse IgG2a and human IgG1 antibodies.50–58 This
ability of FcγRI to contribute to biological signaling has been
attributed to the short half-life of the interaction of FcγRI with its
ligand (turnover within minutes), de novo synthesis of free FcγRI,
receptor reorganization or conformational changes on the
membrane, sampling IgG as a scavenger receptor, and ‘inside-
out’ stimulation by cytokines that rapidly increases the binding of
FcγRI to exogenous monomeric IgG.48,49,51,56,59,60 Indeed we found
that bevacizumab increased FcγRI levels in mouse macrophages
and in wild-type mouse corneas following suture injury (Figure 3c).
More importantly, we found that the concentrations of
endogenous mouse IgG2c (an allelic variant of mouse IgG2a that
is expressed in C57BL/6 mice61,62) in the extravascular portion of
the injured tissues are minute compared with circulating
levels and far lower than the extravascular tissue concentrations
of exogenously administered bevacizumab (Supplementary
Figure 14a and b). This paucity of extravascular mouse IgG
(Supplementary Figure 14c) and the excess of bevacizumab in the
injured tissues combined with increased FcγRI abundance can
explain the ability of the exogenous human IgG1 to bind FcγRI
in vivo on extravascular cells, e.g., macrophages, which express
FcγRI63 and can modulate angiogenesis,64 and initiate signaling.
Numerous therapeutic human IgG1s inhibit angiogenesis via FcγRI
Next we assessed the anti-angiogenic effects of several human or
humanized IgG1 monoclonal antibodies that are approved for
treatment of various human diseases, and either do not bind the
mouse homologs of their intended human protein targets or have
no mammalian target: adalimumab (Humira: anti-TNFα), alemtu-
zumab (Campath: anti-CD52), ofatumumab (Arzerra: anti-CD20),
omalizumab (Xolair: anti-IgE), palivizumab (Synagis: anti-
respiratory syncytial virus protein F), and tocilizumab (Actemra:
anti-IL-6R). All of these human IgG1 antibodies reduced
both corneal and choroidal angiogenesis in wild-type mice
(Figure 4a and b) in contrast to the human IgG2 denosumab
(Figure 2e). We tested two of these antibodies—omalizumab and
palivizumab—in Fcgr1− /− mice, and found that they did not
suppress corneal or choroidal angiogenesis (Figure 4c). We also
found that a mutant version of alemtuzumab (G1Δab), which was
engineered with point mutations in the CH2 domain of its Fc
region that eliminate binding to FcγRI and reduce binding to other
FcγRs,65 yet retains binding to human CD52 (Supplementary
Figure 15a and b), did not inhibit corneal or choroidal angiogen-
esis in wild-type mice (Supplementary Figure 15d and e).
Conversely, we found that another mutant version of alemtuzu-
mab (D270A), which preserves binding to FcγRI but not to FcγRII
and FcγRIII,66,67 suppressed choroidal angiogenesis in wild-type
mice but not in Fcgr1− /− mice (Supplementary Figure 15f).
We sought to exclude the possibility that the observed
angioinhibition could be due to unforeseen or illegitimate
interaction between these human antibodies and the mouse
homologs of their human protein targets by testing them in mice
deficient for the homologous genes. Such interactions were not
responsible for the angiosuppression as we found that corneal
angiogenesis was inhibited by adalimumab in Tnf− /− mice,
alemtuzumab in CD52− /− mice, ofatumumab in CD20− /− mice
and omalizumab in IgE-deficient mice (Figure 4d), just as in wild-
type mice. Collectively, these data indicate that multiple
therapeutic human IgG1 antibodies can suppress angiogenesis
via FcγRI and independent of their intended target.
Next we tested some of these antibodies in FcγR humanized
mice. We found that intracorneal palivizumab reduced corneal
angiogenesis (Figure 4e). In addition, alemtuzumab, but not
alemtuzumab G1Δab, which does not bind FcγRI, suppressed
choroidal angiogenesis in FcγR humanized mice (Supplementary
Figure 16). These data demonstrate that target-independent
angioinhibitory activity of humanized monoclonal IgG1 antibodies
is operative in a FcγR humanized system.
Mouse IgG2a and mouse IgG2c inhibit angiogenesis via FcγRI
To determine whether antibodies potentially produced by
mice against human IgGs might have a role in the angioinhibition
we observed, we tested Rag2− /− mice, which lack B and T cells and
are devoid of Igs. Bevacizumab inhibited corneal and choroidal
angiogenesis in Rag2− /− mice (Supplementary Figure 17), indicat-
ing that such an immune response potentially mounted against
bevacizumab is not responsible for its angioinhibitory effect.
To exclude other potential cross-species biological effects, we
tested mouse IgG2a, which like human IgG1 binds to FcγRI with
high affinity.17,41,57,68,69 Intracorneal or subretinal transfection of a
plasmid encoding mouse IgG2a-Fc coupled to an IL2-secretory
sequence inhibited corneal or choroidal angiogenesis, respec-
tively, in wild-type mice (Supplementary Figure 18). In contrast, a
plasmid encoding a mutant form of mouse IgG2a-Fc engineered
with point mutations that eliminate binding to FcγRI and coupled
to the same IL2-secretory sequence, did not suppress angiogenesis
(Supplementary Figure 18). Recombinant mouse IgG2a-Fc inhibited
choroidal angiogenesis in wild-type mice in a dose-dependent
fashion, whereas mouse IgG2b-Fc, which has high binding affinity for
FcγRIV but not for FcγRI,17,41,43,68,69 did not suppress angiogenesis
(Supplementary Figure 19). In addition, neither recombinant mouse
IgG2a-Fc nor a plasmid encoding mouse IgG2a-Fc reduced
angiogenesis in Fcgr1− /− mice (Supplementary Figure 20). Further,
mouse IgG2c also suppressed choroidal angiogenesis in wild-type
mice but not in Fcgr1− /− mice (Supplementary Figure 21).
Together these data further support the concept that suppression
of angiogenesis via FcγRI is not limited to human IgG1 but also is a
property of mouse IgG2a and mouse IgG2c.
Host Igs modulate angiogenesis
As we found that recombinant and endogenously over-expressed
mouse IgG2a and mouse IgG2c suppressed injury-induced
angiogenesis, we explored whether native host Igs modulate
vascularization. Indeed, we found that corneal and choroidal
angiogenesis responses to suture or laser injury (without adminis-
tration of bevacizumab), respectively, were higher in Fcgr1− /− and
Rag2− /− mice compared with littermate wild-type controls
(Figure 5a and b). Physiological vascularization of the retina during
development proceeds from the central optic nerve to the
periphery. This process is not complete in mice until several days
after birth. We found that at postnatal day 4, both the area of
vascularized retina and density of retinal vessels were greater in
Fcgr1− /− and Rag2− /− mice compared with littermate wild-type
controls (Figure 5c). Taken together, these data suggest an anti-
angiogenic role for endogenous Igs in vascular patterning both
during development and response to injury that is mediated
via FcγRI.
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Human IgG1 reduces angiogenesis via bone marrow-derived cells
expressing FcγRI
To determine whether bone marrow-derived or resident cell
expression of FcγRI was the critical effector in IgG1 mAb-mediated
angioinhibition, we created bone marrow chimeric mice.
Bevacizumab suppressed corneal and choroidal angiogenesis in
Fcgr1− /− mice receiving wild-type bone marrow but did not do so
in wild-type mice receiving Fcgr1− /− bone marrow (Figure 6a and b).
These results suggest that FcγRI in bone marrow-derived cells is
critical for bevacizumab-induced angioinhibition.
Among the various types of bone marrow-derived cells,
macrophages are best known to have a critical role in
angiogenesis.70 Both bevacizumab and human IgG1 inhibited
mouse Vegfa-induced migration of wild-type mouse bone
marrow-derived macrophages (BMDMs) but not of Fcgr1− /−
BMDMs (Figure 6c). Corroborating these data, we found that
Figure 4. Human IgG1s inhibited mouse angiogenesis via FcγRI. Treatment with the human IgG1 antibodies adalimumab, alemtuzumab,
ofatumumab, omalizumab, palivizumab or tocilizumab reduced (a) corneal and (b) choroidal angiogenesis in wild-type mice. n= 8–19.
(c) Palivizumab and Omalizumab did not inhibit corneal or choroidal angiogenesis in Fcgr1−/− mice. n= 6–8. No significant difference between
groups. (d) Adalimumab, a human anti-TNFα monoclonal antibody, inhibited corneal angiogenesis in Tnf−/− mice. n= 9. Alemtuzumab, a
humanized anti-CD52 monoclonal antibody, inhibited corneal angiogenesis in CD52−/− mice. n= 8. Ofatumumab, a human anti-CD20
monoclonal antibody, inhibited corneal angiogenesis in CD20−/− mice. n= 8. Omalizumab, a humanized anti-IgE monoclonal antibody,
inhibited corneal angiogenesis in IgE-deficient mice. n= 10. (e) Palivizumab inhibited choroidal angiogenesis in FcγR humanized mice. Results
are means± s.e.m. *Po0.05 compared with PBS (a, b, d, e).
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bevacizumab reduced the infiltration of F4/80+ macrophages into
the sutured cornea, laser-injured choroid, and ischemic hind limb
of wild-type mice (Supplementary Figure 22). These findings
are in concert with the abundant expression of FcγRI by
macrophages.63,71
We next assessed whether bevacizumab induces intracellular
FcγR-mediated signaling events. First we tested the FcRγ-chain
signaling-deficient NOTAM mice, which exhibit normal cell surface
Fc receptor expression and normal IgG binding, but have non-
signaling Fc receptors because their associated γ-chains have
been mutated in their immunoreceptor tyrosine-based activation
motif, which is responsible for signal transduction.72 We found
that bevacizumab did not suppress choroidal angiogenesis in FcR
NOTAM mice (Figure 6d), suggesting that this angioinhibition is
dependent on FcγR-mediated signaling. Bevacizumab induced
phosphorylation of FcγRI in the mouse cornea (Figure 3b);
therefore, we examined the potential involvement of c-Cbl, a
major regulator of tyrosine kinase signaling that is downstream of
FcγRI-initiated signaling.73,74 We found that bevacizumab induced
phosphorylation of c-Cbl in wild-type but not FcR NOTAM mouse
BMDMs (Figure 6e). This was also corroborated in vivo: increased
phosphorylation of c-Cbl was observed in the corneas of wild-type
mice treated with bevacizumab and bevacizumab-Fc, but not
bevacizumab-Fab, following suture injury (Figure 6f). Neither
bevacizumab nor human IgG1 inhibited mouse Vegfa-induced
migration of c-Cbl− /− BMDMs (Figure 6c). Further, we found that
bevacizumab did not inhibit corneal or choroidal angiogenesis in
c-Cbl− /− mice (Figure 6g), indicating that c-Cbl activation is
essential for this process.
One of the principal signaling pathways employed by mouse
Vegfa to induce macrophage migration is activation of Vegfr1
receptor tyrosine kinase and downstream activation of PI3K and
PLCγ1.75–78 Via its E3 ubiquitin ligase activity, c-Cbl is capable of
inducing degradation of numerous tyrosine kinases including
Vegfr1.79 Indeed, we found that bevacizumab treatment of mouse
macrophages induced degradation of Vegfr1 in wild-type but not
FcR NOTAM BMDMs (Figure 6h). Bevacizumab also reduced mouse
Vegfa-induced phosphorylation of PI3K and PLCγ1 in mouse
macrophages (Figure 6i). Consistent with these findings, neither
bevacizumab nor human IgG1 inhibited mouse Vegfa-induced
migration of BMDMs isolated from c-Cbl (C379A) mutant mice
(Figure 6c), which lack a functional RING finger domain necessary
for the E3 ubiquitin ligase activity of c-Cbl.80 Also consistent
with these findings, and the lack of angioinhibition observed in
c-Cbl− /− mice, was the finding that bevacizumab did not
reduce corneal angiogenesis in c-Cbl (C379A) mutant mice
Figure 5. Endogenous Igs suppressed mouse angiogenesis. Corneal angiogenesis area (a) and choroidal angiogenesis volume (b) are greater
in Fcgr1−/− and Rag2−/− mice compared with wild-type mice. n= 8–20. (c) The vascular density and total area of vascularized retina at postnatal
day 4 is greater in Fcgr1−/− and Rag2−/− mice compared with wild-type mice. n= 8. Results are means± s.e.m. *Po0.05 compared to wild-type
mice (a–c). Vascular density in the retina is normalized to wild-type mice. Representative flat mounts of corneal (a, red), choroidal
(b, green) and retinal (c, red), vessels are shown.
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Figure 6. Bevacizumab inhibited angiogenesis via macrophage FcγRI and c-Cbl. Bevacizumab suppressed corneal (a) and choroidal
(b) angiogenesis in Fcgr1−/− mice transplanted with wild-type mouse bone marrow, but not in wild-type mice receiving Fcgr1−/− bone marrow.
n= 11–16. (c) Bevacizumab and human IgG1 inhibited mouse Vegfa-induced migration, over 12 h, of bone marrow-derived macrophages
isolated from wild-type mice but not from Fcgr1−/−, c-Cbl−/− or c-Cbl (C379A) mice, which lack E3 ubiquitin ligase activity. n= 3. Results are
means±s.e.m. *Po0.05 compared with PBS (a–c). (d) Bevacizumab did not inhibit choroidal angiogenesis in NOTAM mice. n= 10. (e) Western
blot shows induction of c-Cbl phosphorylation in wild-type mouse BMDMs treated with bevacizumab for 15 min. Protein loading was assessed
by α-Tubulin abundance. (f) Western blot shows in vivo induction of c-Cbl phosphorylation in wild-type mouse corneas following suture injury
that were treated with bevacizumab or its Fc fragment, but not by its Fab fragment. (g) Bevacizumab did not inhibit corneal or choroidal
angiogenesis in c-Cbl−/− mice. n= 11–30. NS, no significant difference between groups. (h) Western blots show time-dependent Vegfr1
degradation in wild-type but not NOTAM mouse BMDMs treated with bevacizumab. Protein loading was assessed by HSP70 abundance.
(i) Western blots show that RAW264.7 mouse macrophages pre-treated with bevacizumab, but not PBS, 2 h before stimulation with mouse
Vegfa, exhibited reduced phosphorylation of PI3K and PLCγ1 at 10 min after Vegfa exposure. Protein loading was assessed by β-actin
abundance. (j) Western blots show induction of c-Cbl phosphorylation in human peripheral blood mononuclear cells (PBMC) or in THP-1
human monocytic cells, treated with bevacizumab, but not PBS, for 15 min. Treatment with bevacizumab, but not PBS, reduced VEGFR1
abundance in human PBMCs and THP-1 cells. Protein loading was assessed by Vinculin or α-Tubulin abundance. Images representative of
three experiments (e, f, h–j).
Generic suppression of angiogenesis by antibodies
S Bogdanovich et al
10
Signal Transduction and Targeted Therapy (2016) 15001 © 2016 West China Hospital, Sichuan University
(Supplementary Figure 23). We also found that bevacizumab
induced phosphorylation of c-CBL and degradation of VEGFR1 in
primary human peripheral blood monocytes as well as in THP-1
human monocytes (Figure 6j).
Human IgG1 does not inhibit angiogenesis via ADCC, ADCP
or CDC
Antibody-dependent cell-mediated cytotoxicity (ADCC) and
antibody-dependent cellular phagocytosis (ADCP) are two-step
processes initiated by full-length IgGs that couple Fab binding
to a target cell antigen with Fc binding to an activating FcγR on
an effector cell.71 These effector functions, as well as
complement-dependent cytotoxicity (CDC) have a major role in
the mode of action of several monoclonal antibodies employed
in cancer therapy.81–83 Our findings that numerous human
IgG1 antibodies, each with different Fab targeting domains
(and none of which target mouse antigens), similarly suppressed
angiogenesis argue against ADCC and ADCP as the mediators of
this class effect. Moreover, bevacizumab-Fc and human IgG1-Fc,
each devoid of Fab domains, also suppressed angiogenesis
like full-length antibodies. We have already shown that
bevacizumab inhibited corneal and choroidal angiogenesis in
mice lacking FcγRIII, a receptor on NK cells that mediates
ADCC,84 and in mice lacking FcγRIV, which also has an important
role in ADCC85 (Supplementary Figures 8 and 9). In addition,
bevacizumab inhibited corneal and choroidal angiogenesis in
Il2rg−/− mice, which are deficient in NK cells (Supplementary
Figure 24). These data support the thesis that this effector
function is not involved in the angioinhibitory effect of
bevacizumab in mice.
The inability of denosumab to suppress corneal or choroidal
angiogenesis suggests that ADCC and CDC, which can be induced
by both human IgG1 and human IgG2,86 are not responsible for
angioinhibition induced by human IgG1s. We also found that a
mutant version of alemtuzumab (G1Δa), which was engineered
with point mutations in the CH2 domain of its Fc region that
eliminate its CDC activity, yet retains binding to human CD52 and
to FcγRI (Supplementary Figure 15a–c), inhibited corneal
and choroidal angiogenesis in wild-type mice (Supplementary
Figure 15d and e). In addition, bevacizumab suppressed choroidal
angiogenesis in C1qa− /− mice (Supplementary Figure 25), which
are deficient in complement C1QA, confirming that the angioin-
hibitory activity of human IgG1 antibodies does not require CDC.
Subretinal transfection of a plasmid encoding a mutant form of
human IgG1-Fc engineered with the K322A or D270A point
mutations, which eliminates binding to C1q and induction of CDC
while preserving binding to FcγRI,66,67,87 also reduced choroidal
angiogenesis in wild-type mice (Supplementary Figure 26).
Collectively, these data support the concept that angioinhibition
is a target-independent class effect of human or humanized IgG1
monoclonal antibodies that is mediated via FcγRI, and not ADCC,
ADCP or CDC.
DISCUSSION
We have shown that human or humanized IgG1 antibodies are, as
a class, angioinhibitory in multiple mouse models of ocular and
muscle angiogenesis via Fc-dependent signaling. Our findings
introduce angiosuppression to the list of important biological
functions that are triggered by FcγRI in vivo.57 Exploiting this
intrinsic property of human IgG1s could offer new therapeutic
opportunities to treat diseases driven by angiogenesis that
collectively affect nearly 10% of the world’s population.20 For
example, several human IgG1 drugs or human IgG1-Fc fusion
proteins approved for other indications could be repurposed as
angiogenesis inhibitors. IVIg or non-targeted, ‘generic’ human IgG-
Fc might represent even more inexpensive alternatives, as we
demonstrate in a companion manuscript.88 Additional anti-
angiogenic efforts might be directed toward developing peptides
or small molecules that induce signaling via FcγRI or c-Cbl.
The dose of bevacizumab (100 μg) we injected into the mouse
cornea, whose volume is ~ 2 μl, is similar in concentration to the
dose of bevacizumab (2.5–5 mg) that has been administered into
human corneas, whose volume is ~ 70 μl. Our findings suggest
that in human corneas, bevacizumab would, at this dose, exert
anti-angiogenic activity both via VEGFA inhibition and via FcγRI-
mediated pathways, and that it might be expected to suppress
angiogenesis to a greater extent than ranibizumab, which
possesses only the anti-VEGFA activity. Indeed, a recent prospec-
tive randomized study reported that in humans with corneal
angiogenesis, bevacizumab was superior to ranibizumab.18
In contrast, no significant difference was found between
bevacizumab and ranibizumab in human eyes with choroidal
angiogenesis due to neovascular AMD.4,19 We suggest that the
reason for this lack of difference is that the amount of
bevacizumab that is currently administered in these patients,
while sufficient to neutralize VEGFA, is insufficient to induce FcγRI-
mediated signaling. The dose of intravitreously administered
bevacizumab required to suppress choroidal angiogenesis via
FcγRI in mice (25 μg) translates, based on relative vitreous humor
volumes, to ~ 10 mg in the human eye, which is eightfold the
currently administered clinical dose. These values are compatible
with
the relative lower affinity of human IgG1-Fc for human FcγRI
(KD = 15–40 nmol/l)
45,56,89 compared with that of bevacizumab for
human VEGFA (KD = 0.5–2.2 nmol/l).
3,5 Our findings predict that a
eightfold higher dose bevacizumab would achieve both VEGFA
inhibition and FcγRI-mediated angioinhibition, and provide a
rationale for testing such higher doses of bevacizumab or
combining human IgG1-Fc to anti-human VEGFA drugs in patients
with neovascular AMD to potentiate therapeutic angioinhibition.
It is reasonable to query whether it would be possible to inject
10 mg of bevacizumab into the human eye. The viability of
injecting 10 mg of a biological drug has been demonstrated in a
Phase 2 trial of lampalizumab, a Fab fragment. At present in the
clinic, 1.25 mg of bevacizumab is injected in a 50-μl volume. Retina
specialists routinely inject 100 μl of corticosteroids or 200 μl of
antibiotics into the vitreous humor of humans for various
disorders. With such higher delivery volumes, 10 mg of bevacizu-
mab can be administered by increasing the concentration of the
formulation from the current 25 mg/ml to 50–100 mg/ml, a value
similar to that of therapeutic human IVIg preparations in current
use. Alternatively, bevacizumab-Fc or human IgG1-Fc could be
administered, at correspondingly lower doses, to induce FcγRI-
dependent angioinhibition.
It would be interesting to explore to what extent the
therapeutic effects of IgG1 antibodies used in the treatment of
AMD, arthritis, asthma and solid tumors—disorders in which
angiogenesis plays a critical role20—might be mediated by FcγRI.
Our data also suggest that it might be prudent to monitor
potential effects of human IgG1 antibodies on the vasculature in
other diseases, as we demonstrate is the case in IVIg-treated
patients in a companion manuscript.88 Indeed, the minimal
angioinhibitory dose of bevacizumab in mice, 15 mg/kg, is used
in humans with many forms of cancer, suggesting that at this dose
in people, the drug might have dual anti-angiogenic activity: via
VEGFA inhibition and FcγRI-dependent pathways. Although most
human IgG1 antibodies are administered systemically at doses of
5–10 mg/kg, several are administered at 15 mg/kg and some as
high as 30 mg/kg. Whether these antibodies might modulate
other cellular processes, apart from angioinhibition, via FcγRI/c-Cbl
signaling also merits future study. Such effects, if they occur, could
be mitigated by the use of miniaturized configurations such as Fab
or single chain variable fragments, fully deglycosylated antibodies,
or Fc region engineering. Prolonged and frequent therapeutic IgG
Generic suppression of angiogenesis by antibodies
S Bogdanovich et al
11
© 2016 West China Hospital, Sichuan University Signal Transduction and Targeted Therapy (2016) 15001
injections could potentially interfere with natural activation of
FcγRs by endogenous IgGs. Therefore, targeted local therapy on
an intermittent basis might be preferable for the treatment of
chronic diseases.
Our bone marrow chimera experiments point to FcγRI on
circulating myeloid cells as being critical for bevacizumab-induced
angioinhibition. In human AMD as well as murine laser-induced
angiogenesis, macrophages are highly spatially and temporally
coincident with areas of choroidal neoangiogenesis.64,90 Indeed, of
the various circulating myeloid cells in mice, only macrophages
express FcγRI.91 Furthermore, we documented a reduction in
macrophage infiltration following bevacizumab treatment that
corresponds to angioinhibition. Nevertheless, in addition to
disrupting Vegfr1 levels and signaling in macrophages, FcγRI-
mediated events might also affect other myeloid cells, endothelial
cells, or their bone marrow-derived precursors, and could
transduce complex crosstalk among these cell types to modulate
angiogenesis. Signaling pathways downstream of c-Cbl activation,
as well as other yet to be determined molecular signals triggered
via FcγRI, could be additionally responsible for human IgG1-
induced angioinhibition.
Our data suggest that endogenous Igs could have a homeo-
static role in modulating physiological or pathological angiogen-
esis. Future studies could explore the extent to which Igs regulate
developmental vasculature. Polymorphisms in various FCGR genes
have been associated with clinical responses to certain mono-
clonal antibodies in cancer.92 It would be interesting to explore
whether variants in FCGR1 might affect the vascular status or
clinical response of patients to various human IgG1 antibodies,
when they are administered at doses that would be expected to
induce FcγRI-mediated signaling.
Our studies, which have identified an unexpected vascular
effect of widely used drugs, highlight the importance of
employing rigorous biological controls for studies of IgGs. In
revealing the intrinsic anti-angiogenic capacity of Fc-containing
human IgG1s, these findings could be instructive in the future
design and use of antibody-based therapeutics, expand under-
standing of the biological links between immunity and angiogen-
esis, and potentially enable novel angioinhibitory therapies.
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